Results 11 to 20 of about 20,247 (196)

Engineering TME-activated CD47-specific CAR macrophage via Arg1 promoter for safe and effective solid tumor immunotherapy [PDF]

Journal for ImmunoTherapy of Cancer
Background Chimeric antigen receptor macrophage (CAR-Mφ) therapy has promising therapeutic potential in solid tumors, yet challenges remain in target compatibility and systemic toxicity.Methods In this study, we screened the CD47-scFv sequence of CAR-Mφ ...
Min Liu, Xinyi Xu, Haotian Zhang, Anna He, Lili Lu, Fuyu Du, Meixi Jiang, Jingjing Qiu, Yuanhui Xu, Xiaocheng Gong, Xinruo Wang, Xianghan Zhang, Zhongliang Wang, Pengbo Ning   +13 more
doaj   +2 more sources

Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance [PDF]

Journal for ImmunoTherapy of Cancer
Background Tumor-associated macrophages (TAMs) abundantly infiltrate tumors and possess potent antitumor capabilities. “Don‘t eat me” signals like CD47 allow tumors to evade macrophages and proliferate unchecked.
Chao Wang, Juan Zhang, Yi Luo, Yifei Wang, Weifeng Huang, Shaogang Peng, Andy Tsun, Xiaoniu Miao, Liandi Chen, Lidi Nan, Huayuan Liao, Ziyue Cui, Yanqing Lv, Xiaomu Wang   +13 more
doaj   +2 more sources

CD47 expression is critical for CAR T-cell survival in vivo

Journal for ImmunoTherapy of Cancer, 2023
Background CD47 is an attractive immunotherapeutic target because it is highly expressed on multiple solid tumors. However, CD47 is also expressed on T cells.
Stephen Gottschalk, Phuong Nguyen, Christopher DeRenzo, Giedre Krenciute, Alex N Beckett, Peter Chockley, Shondra M Pruett-Miller, Peter Vogel, Heather Sheppard   +8 more
doaj   +1 more source

Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer

Molecular Therapy: Oncolytics, 2021
Chimeric antigen receptor (CAR) T cells have revolutionized blood cancer immunotherapy; however, their efficacy against solid tumors has been limited. A common mechanism of tumor escape from single target therapies is downregulation or mutational loss of
Runzhe Shu, Vera J. Evtimov, Maree V. Hammett, Nhu-Y N. Nguyen, Junli Zhuang, Peter J. Hudson, Maureen C. Howard, Aleta Pupovac, Alan O. Trounson, Richard L. Boyd   +9 more
doaj   +1 more source

Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis

Journal of Immunology Research, 2021
CD47 is a cell surface glycoprotein molecule, belonging to the immunoglobulin superfamily, binding to various proteins including integrins, thrombospondin-1, and signal regulatory protein α (SIRPα).
Huyen Thi La, Dao Bich Thi Tran, Hai Manh Tran, Linh Trong Nguyen   +3 more
doaj   +1 more source

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo

Frontiers in Oncology, 2022
Targeted therapies hold promise for efficiently and accurately delivering cytotoxic drugs directly to tumor tissue to exert anticancer effects. CD47 is a membrane protein expressed in a variety of malignant tumors and hematopoietic cells, which plays a ...
Zu-Chian Chiang, Zu-Chian Chiang, Zu-Chian Chiang, Shubin Fang, Yang-kun Shen, Dongya Cui, Huanjiao Weng, Dawei Wang, Yuxiang Zhao, Jizhen Lin, Jizhen Lin, Qi Chen   +11 more
doaj   +1 more source

Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice

OncoImmunology, 2022
CD47 has established roles in the immune system for regulating macrophage phagocytosis and lymphocyte activation, with growing evidence of its cell-intrinsic regulatory roles in natural killer and CD8+ T cells.
Pulak R. Nath, Dipasmita Pal-Nath, Sukhbir Kaur, Arunkumar Gangaplara, Thomas J. Meyer, Margaret C Cam, David D. Roberts   +6 more
doaj   +1 more source

CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells [PDF]

Clinical Cancer Research, 2015
Abstract Purpose: Artificial antigen-presenting cells, aAPC, have successfully been used to stimulate antigen-specific T-cell responses in vitro as well as in vivo. Although aAPC compare favorably with autologous dendritic cells in vitro, their effect in vivo might be diminished through rapid clearance by macrophages.
Heiko, Bruns, Catherine, Bessell, Juan Carlos, Varela, Carl, Haupt, Jerry, Fang, Shirin, Pasemann, Andreas, Mackensen, Mathias, Oelke, Jonathan P, Schneck, Christian, Schütz   +9 more
openaire   +2 more sources

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy

Frontiers in Immunology, 2021
The prosperity of immunological therapy for cancer has aroused enormous passion for exploiting the novel targets of cancer immunotherapy. After the approval of blinatumomab, a bispecific antibody (bsAb) targeting on CD19 for acute lymphoblastic leukemia,
Yan Yang, Zheng Yang, Yun Yang
doaj   +1 more source

CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice. [PDF]

PLoS ONE, 2012
How do effector CD4 T cells escape cell death during the contraction of the immune response (IR) remain largely unknown. CD47, through interactions with thrombospondin-1 (TSP-1) and SIRP-α, is implicated in cell death and phagocytosis of malignant cells.
Vu Quang Van, Nobuyasu Baba, Manuel Rubio, Keiko Wakahara, Benoit Panzini, Carole Richard, Genevieve Soucy, Denis Franchimont, Genevieve Fortin, Ana Carolina Martinez Torres, Lauriane Cabon, Santos Susin, Marika Sarfati   +12 more
doaj   +1 more source